Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Apr 11, 2021 12:27pm
98 Views
Post# 32974337

RE:RE:Melanoma & Colorectal

RE:RE:Melanoma & ColorectalYep -  all good stuff.  I passed the links along to an analyst to see if it would elicit any excitement or critique for us.  Will see if it does.  I'm guessing it's the kind of thing they would ignore until a Phase 1 complete or Phase 2.  To me, finding something highly effective and massively more safe would be worth understanding.  I'll see if he thinks so too.

scarlet1967 wrote: "The colorectal is also interesting since it does show docetaxel has basically no effect yet TH1902 does."

Great to see, the presentation was easy to follow ,couple of things were emphasized one low concentration (a quarter of the dose) of TH 1902 PDC showed  full activity in  TNB cancer, melanoma and endometrial cancer versus docetaxel alone not showing any activity when administered in low dose.
Docetaxel has no activity in colorectal cancer versus TH1902 PDC which showed significant activity.
 


<< Previous
Bullboard Posts
Next >>